OKYO Pharma Ltd - life sciences and biotechnology company - Submits a patent application for the potential use of chemerin and chemerin analogues for prophylaxis against and treatment of symptoms associated with, or resulting from, infection with SARS-CoV-2 virus, including inflammation due to the cytokine storm caused by Covid-19, and acute respiratory distress syndrome. "We are working aggressively to expand this Covid-19 work and will be providing progress on this project as important developments occur," says Gary Jacob, chief executive of OKYO.
Current stock price: 11.40 pence, down 0.9% on Tuesday
Year-to-date change: up 49%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.